136 related articles for article (PubMed ID: 1650660)
1. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Curr Eye Res; 1991; 10 Suppl():139-42. PubMed ID: 1650660
[TBL] [Abstract][Full Text] [Related]
2. Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits.
Maudgal PC; De Clercq E
Antiviral Res; 1991 Jul; 16(1):93-100. PubMed ID: 1663731
[TBL] [Abstract][Full Text] [Related]
3. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Invest Ophthalmol Vis Sci; 1991 May; 32(6):1816-20. PubMed ID: 1851733
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.
Maudgal PC; De Clercq E; Huyghe P
Invest Ophthalmol Vis Sci; 1987 Feb; 28(2):243-8. PubMed ID: 8591903
[TBL] [Abstract][Full Text] [Related]
5. Experimental thymidine kinase-deficient HSV-1 keratitis: therapeutic attempts.
Maudgal PC; De Clercq E; Huyghe P
Curr Eye Res; 1987 Apr; 6(4):579-84. PubMed ID: 2953558
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo.
De Clercq E; Holý A; Rosenberg I
Antimicrob Agents Chemother; 1989 Feb; 33(2):185-91. PubMed ID: 2719463
[TBL] [Abstract][Full Text] [Related]
7. Experimental stroma herpes simplex keratitis. Influence of treatment with topical bromovinyldeoxyuridine and trifluridine.
Maudgal PC; De Clercq E; Descamps J; Missotten L; Wijnhoven J
Arch Ophthalmol; 1982 Apr; 100(4):653-6. PubMed ID: 6803747
[TBL] [Abstract][Full Text] [Related]
8. Ac2IDU, BVDU, and thymine arabinoside therapy in experimental herpes keratitis.
Hettinger ME; Pavan-Langston D; Park NH; Albert DM; De Clercq E; Lin TS
Arch Ophthalmol; 1981 Sep; 99(9):1618-21. PubMed ID: 7283815
[TBL] [Abstract][Full Text] [Related]
9. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of bromovinyldeoxyuridine in the treatment of herpes simplex virus and varicella-zoster virus eye infections.
Maudgal PC; De Clercq E; Missotten L
Antiviral Res; 1984 Oct; 4(5):281-91. PubMed ID: 6335020
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine.
Foster SA; Cerny J; Cheng YC
J Biol Chem; 1991 Jan; 266(1):238-44. PubMed ID: 1845964
[TBL] [Abstract][Full Text] [Related]
12. (E)-5-(2-bromovinyl)-2'-Deoxyuridine in the treatment of experimental herpes simplex keratitis.
Maudgal PC; De Clercq E; Descamps J; Missotten L; De Somer P; Busson R; Vanderhaeghe H; Verhelst G; Walker RT; Jones AS
Antimicrob Agents Chemother; 1980 Jan; 17(1):8-12. PubMed ID: 7352751
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of bromovinyldeoxyuridine-related compounds in the treatment of experimental herpes simplex keratitis.
Maudgal PC; De Clercq E
Arch Ophthalmol; 1985 Sep; 103(9):1393-7. PubMed ID: 4038133
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil against acute herpes simplex virus keratitis and the establishment of latency: comparison with acyclovir and bromovinyldeoxyuridine.
Rajcáni J; Reefschläger J
Acta Virol; 1987 Aug; 31(4):329-39. PubMed ID: 2892382
[TBL] [Abstract][Full Text] [Related]
15. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents.
Maudgal PC; De Clercq E
Curr Eye Res; 1991; 10 Suppl():193-9. PubMed ID: 1650667
[TBL] [Abstract][Full Text] [Related]
16. Properties of a 9-(2-phosphonylmethoxyethyl)adenine (PMEA)-resistant herpes simplex virus type 1 virus mutant.
Vonka V; Anisimová E; Cerný J; Holý A; Rosenberg I; Votruba I
Antiviral Res; 1990 Aug; 14(2):117-21. PubMed ID: 2177316
[TBL] [Abstract][Full Text] [Related]
17. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
18. Ocular penetration and efficacy of chloroethyldeoxyuridine against herpetic keratouveitis.
Maudgal PC; De Clercq E; Bernaerts R; Dieltiens M; Breemersch M; Van Eeckhoutte L
Invest Ophthalmol Vis Sci; 1986 Oct; 27(10):1453-8. PubMed ID: 3759363
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) in the treatment of experimental herpes simplex virus type 1 keratitis in rabbits: comparison with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BrVUdR).
Töpke H; Gräf M; Wutzler P; Herrmann G; Reefschläger J
Antiviral Res; 1988 Jul; 9(4):273-80. PubMed ID: 3202622
[TBL] [Abstract][Full Text] [Related]
20. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
